Skip to main content
Journal cover image

Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.

Publication ,  Journal Article
Khan, MS; Fonarow, GC; Greene, SJ
Published in: Eur J Heart Fail
June 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

June 2021

Volume

23

Issue

6

Start / End Page

1023 / 1025

Location

England

Related Subject Headings

  • Symporters
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium
  • Humans
  • Heart Failure
  • Glucose
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khan, M. S., Fonarow, G. C., & Greene, S. J. (2021). Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. Eur J Heart Fail, 23(6), 1023–1025. https://doi.org/10.1002/ejhf.2170
Khan, Muhammad Shahzeb, Gregg C. Fonarow, and Stephen J. Greene. “Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.Eur J Heart Fail 23, no. 6 (June 2021): 1023–25. https://doi.org/10.1002/ejhf.2170.
Khan, Muhammad Shahzeb, et al. “Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.Eur J Heart Fail, vol. 23, no. 6, June 2021, pp. 1023–25. Pubmed, doi:10.1002/ejhf.2170.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

June 2021

Volume

23

Issue

6

Start / End Page

1023 / 1025

Location

England

Related Subject Headings

  • Symporters
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium
  • Humans
  • Heart Failure
  • Glucose
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology